Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01457079Unknown

Keloid Radiation Registry

Role: lead

NCT01478243Terminated

Study of Psycho-Social Impact of Keloid

Role: lead

NCT01423383Unknown

Epidemiology Study of Keloid

Role: lead

NCT01408953Phase 2Terminated

Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Role: lead

NCT01425216Phase 2Terminated

Sorafenib for Patients With Extensive Keloids

Role: lead

NCT01423981Recruiting

Web Based Investigation of Natural History of Keloid Disorder, an Online Survey

Role: lead

NCT02923596Unknown

Retrospective Study of Keloid Disorder

Role: lead

NCT01425437Terminated

Keloid Tissue Bank

Role: lead

All 8 trials loaded